United States Pharmaceuticals and Healthcare Report Q2 2016

114 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: The US pharmaceutical market is, and will continue to remain, the most attractive globally.
Due to ongoing challenges in Western Europe and emerging markets, drug companies should increasingly
prioritise the US for commercialisation efforts, as well as R&D and manufacturing investments. The key
downside risk to this positive outlook is increased pricing pressure from the government and other payers.
Headline Expenditure Projections
? Pharmaceuticals: USD333.4bn in 2015 to USD349.9bn in 2016; +4.9% growth. Market forecast revised
upwards since Q116 due to consideration and incorporation of new company sales data.
? Healthcare: USD3.1trn in 2015 to USD3.3trn in 2016; +5.0% growth. Forecast unchanged since Q315.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (United States 2014-2020) 7
SWOT 10
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (United States 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020) 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020) 22
Patented Drug Market Forecast 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (United States 2012-2020) 30
Pharmaceutical Trade Forecast 31
Table: Pharmaceutical Trade Data And Forecasts (United States 2014-2020) 32
Industry Risk Reward Index 33
Americas Risk/Reward Index 33
United States Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Intellectual Property Issues 56
Pricing & Reimbursement Regime 57
Late-2013 Government Shutdown 59
The November 2016 Presidential Election 61
Market Overview 63
Healthcare Sector 64
Table: Key Features Of The Affordable Care Act By Year 66
Table: Healthcare Resources (United States 2010-2015) 69
Table: Healthcare Personnel (United States 2010-2015) 69
Table: Healthcare Activity (United States 2010-2015) 70
Clinical Trials 70
Epidemiology 72
Competitive Landscape 75
Research-Based Industry 75
Table: Multinational Market Activity 75
Pharmaceutical Distribution 77
Pharmaceutical Retail Sector 77
Company Profile 78
Amgen 78
AstraZeneca 83
Eli Lilly 87
GlaxoSmithKline 91
Merck & Co 95
Pfizer 99
Demographic Forecast 103
Table: Population Headline Indicators (United States 1990-2025) 104
Table: Key Population Ratios (United States 1990-2025) 104
Table: Urban/Rural Population & Life Expectancy (United States 1990-2025) 105
Table: Population By Age Group (United States 1990-2025) 105
Table: Population By Age Group % (United States 1990-2025) 106
Glossary 108
Methodology 110
Pharmaceutical Expenditure Forecast Model 110
Healthcare Expenditure Forecast Model 110
Notes On Methodology 111
Risk/Reward Index Methodology 112
Index Overview 113
Table: Pharmaceutical Risk/Reward Index Indicators 113
Indicator Weightings 114

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (United States 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (United States 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (United States 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (United States 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (United States 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (United States 2014-2020)
Table: Key Features Of The Affordable Care Act By Year
Table: Healthcare Resources (United States 2010-2015)
Table: Healthcare Personnel (United States 2010-2015)
Table: Healthcare Activity (United States 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (United States 1990-2025)
Table: Key Population Ratios (United States 1990-2025)
Table: Urban/Rural Population & Life Expectancy (United States 1990-2025)
Table: Population By Age Group (United States 1990-2025)
Table: Population By Age Group % (United States 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Ecuador Pharmaceuticals and Healthcare Report Q2 2016BMI View: Pharmaceutical companies will continue to benefit from Ecuador's growing demand for medicines due to the government's commitment to healthcare. Going forward, we expect the government to continue increasing national health spending, take steps to expand public health insurance coverage and reform the IESS to alleviate access challenges - increasing the scope of opportunities for would-be investors. Headline Expenditure Projections Pharmaceuticals: USD1.6bn in 2015 to […]
  • Thailand Pharmaceuticals and Healthcare Report Q2 2016BMI View: Multinational drugmakers will continue to face a difficult business environment in Thailand. Designated as a 'Priority Watch List Country' for PhRMA's Special 301 submission for 2016, key issues highlighted in 2015 remain unaddressed. This includes low levels of intellectual property protection as well as a challenging procurement process that favours the Government Procurement Organization. Cost containment pressures will also become more acute as authorities seek to curb […]
  • Kazakhstan Pharmaceuticals and Healthcare Report Q2 2015BMI View: Within the pharmaceutical sector, the Kazakh government is looking to reduce its import reliance and also to serve its growing healthcare needs. In light of the Kazakh government's commitment to ramping up healthcare expenditure and incentivising foreign investment, we believe multinational companies will localise manufacturing to a limited extent. Given the logistical challenges, limited skilled labour and a lack of necessary infrastructure, we expect that investment in […]
  • Moldova Pharmaceuticals and Healthcare Report Q2 2016BMI View: Moldova's pharmaceutical market presents very limited opportunities for multinational drugmakers, in comparison to its neighbours in Eastern Europe. The country's small total market size and its reliance on out-of-pocket payments highlight the challenges it poses. Moldova's economic outlook, which is defined by its relations with Russia and the EU, will play a significant role in how the market grows over the coming years. Headline Expenditure Projections ? Pharmaceuticals: […]
  • Nigeria Pharmaceuticals and Healthcare Report Q2 2016BMI View: Nigeria's prospects of attaining national health coverage will largely depend upon the success of the National Health Act. This, however, will continue to face a number of challenges that have previously led to delays in its implementation. The eventual rollout of the act will make Nigeria an attractive prospect for multinational drugmakers over the long-term, though political and fiscal barriers limit the successful likelihood of its implementation and subsequent […]